Innoviva Inc (INVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innoviva Inc (INVA) has a cash flow conversion efficiency ratio of 0.046x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($54.51 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Innoviva Inc's balance sheet to measure how much of total assets are equity-financed.
Innoviva Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Innoviva Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INVA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Innoviva Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innoviva Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
-0.135x |
|
ELECTROLUX B ADR/2 SK 5
F:ELXA
|
-0.516x |
|
Airport City Ltd
TA:ARPT
|
0.013x |
|
Sanyang Motor Co Ltd
TW:2206
|
-0.006x |
|
Lakeland Financial Corporation
NASDAQ:LKFN
|
0.047x |
|
Yantai China Pet Foods Co Ltd
SHE:002891
|
0.000x |
|
Fair Oaks Income Limited
LSE:FAIR
|
0.168x |
|
Qingdao Doublestar Co Ltd
SHE:000599
|
0.002x |
Annual Cash Flow Conversion Efficiency for Innoviva Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Innoviva Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Innoviva Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.17 Billion | $196.93 Million | 0.168x | -38.50% |
| 2024-12-31 | $691.16 Million | $188.69 Million | 0.273x | +30.63% |
| 2023-12-31 | $674.96 Million | $141.06 Million | 0.209x | -41.38% |
| 2022-12-31 | $565.79 Million | $201.73 Million | 0.357x | -48.46% |
| 2021-12-31 | $525.93 Million | $363.81 Million | 0.692x | +34.29% |
| 2020-12-31 | $607.84 Million | $313.11 Million | 0.515x | -31.55% |
| 2019-12-31 | $342.12 Million | $257.46 Million | 0.753x | -46.45% |
| 2018-12-31 | $159.05 Million | $223.53 Million | 1.405x | +340.64% |
| 2017-12-31 | $-242.71 Million | $141.75 Million | -0.584x | -238.05% |
| 2016-12-31 | $-352.99 Million | $60.98 Million | -0.173x | -484.31% |
| 2015-12-31 | $-342.64 Million | $10.13 Million | -0.030x | -105.05% |
| 2014-12-31 | $-223.35 Million | $-130.72 Million | 0.585x | +235.08% |
| 2013-12-31 | $299.12 Million | $-129.60 Million | -0.433x | +47.50% |
| 2012-12-31 | $155.03 Million | $-127.95 Million | -0.825x | -181.33% |
| 2011-12-31 | $-87.05 Million | $-88.34 Million | 1.015x | -69.72% |
| 2010-12-31 | $-22.42 Million | $-75.14 Million | 3.352x | +990.94% |
| 2009-12-31 | $-188.99 Million | $-58.06 Million | 0.307x | -58.50% |
| 2008-12-31 | $-134.95 Million | $-99.91 Million | 0.740x | -53.00% |
| 2007-12-31 | $-66.26 Million | $-104.37 Million | 1.575x | +195.16% |
| 2006-12-31 | $63.31 Million | $-104.79 Million | -1.655x | -68.17% |
| 2005-12-31 | $59.58 Million | $-58.65 Million | -0.984x | -291.79% |
| 2004-12-31 | $190.37 Million | $-47.82 Million | -0.251x | -337.58% |
| 2003-12-31 | $-299.57 Million | $-31.68 Million | 0.106x | -58.15% |
| 2002-12-31 | $-231.93 Million | $-58.60 Million | 0.253x | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more